Bio-Techne TECH 深 沪
已收盘 10-09 16:00:00 美东时间
72.46
+0.010
+0.01%
华盛通- 最 高72.52
- 今 开72.46
- 成交量 222.80万股
- 最 低 72.44
- 昨 收 72.45
- 总市值 113.63亿
- 52周最高 72.69
- 市盈率 静 62.56
- 换手率 1.42%
- 52周最低 43.035
- 委 比 67.60%
- 总股本 1.57亿
- 历史最高 134.3625
- 量 比 0.72
- 振 幅 0.11%
- 历史最低 11.5325
- 每 手 1
- 风险率 8.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bio-Techne Opens New Bristol Facility
Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America Combined capabilities across Bristol, St. Paul and Minneapolis support cus...
10-08 20:09
113亿美元豪赌Bio-Techne，默克真正想买的是什么？
（来源：精化大不同） 导读 全球生命科学领域，又一笔百亿美元级并购迎来关键进展。Bio-Techne股东已经批准德国默克的收购方案。 按此前交易协议...
09-29 18:01
Bio-Techne Receives Shareholders' Approval For Proposed Acquisition By Merck KGaA
Bio-Techne Corporation (NASDAQ:TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "M...
09-23 21:22
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bi...
09-23 21:20
Bio-Techne Announces SBTi Validation Of 70% Scope 1 & 2 Emissions Reduction Target By FY2031 And Supplier Engagement Commitment, Reporting Significant Operational Emissions Cuts In FY2026
Fiscal 2026 highlights: Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the company's electricity consumption now comes from renewable sources First comprehensi...
09-01 18:36
财报速睇 | Bio-Techne 2026财年年度营收12.15亿美元，同比下降0.4%；归母净利润1.82亿美元，同比增长149.3%
华盛资讯8月25日讯，Bio-Techne公布2026财年年度业绩，公司年度营收12.15亿美元，同比下降0.4%，归母净利润1.82亿美元，同比增长149.3%。
08-25 04:47
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.
08-14 05:36
Bio-Techne Corrects Dividend Announcement
MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stat...
08-13 18:30
